Stanhope, AIMCo and Mitsui Fudosan have announced that Novartis are moving their UK headquarters to The WestWorks in White City Place. Novartis will become the latest in a series of life science companies to take up residence in White City Place, which is cementing itself as an integral part of the emerging west London life sciences cluster, which has become a beacon for innovative and advanced tech and life sciences companies. Novartis will take up residence on the second floor, initially be occupying 54,000 sq. ft. of space in March 2019, with the option to expand further to 65,000 sq. ft, and will move in by January 2020.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs, including innovative medicines, cost-saving pharmaceuticals and eye care. In 2017 Novartis invested almost £30million in R&D and is a leading sponsor of clinical trials in the UK.
David Camp, Chief Executive of Stanhope, said: “We are delighted that Novartis has chosen WestWorks at White City Place as their new headquarters in the UK. The addition of Novartis to WestWorks shows the growth of science and innovation within White City, the best new neighbourhood in London.”